Good evening :)
Place Order
Add to Watchlist

Panacea Biotec Ltd

PANACEABIO

Panacea Biotec Ltd

PANACEABIO
Health CareBiotechnology
SmallcapWith a market cap of ₹2,627 cr, stock is ranked 999
High RiskStock is 4.33x as volatile as Nifty
414.353.43% (-14.70)
414.353.43% (-14.70)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
SmallcapWith a market cap of ₹2,627 cr, stock is ranked 999
High RiskStock is 4.33x as volatile as Nifty

How to use scorecard? Learn more

Health CareBiotechnology
SmallcapWith a market cap of ₹2,627 cr, stock is ranked 999
High RiskStock is 4.33x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-171.093.11
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.176.510.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.

PE Ratio
46.51
1Y Return
33.11%
Buy Reco %
68.75
PE Ratio
-45.31
1Y Return
11.11%
Buy Reco %
PE Ratio
186.09
1Y Return
1.92%
Buy Reco %
100.00
PE Ratio
51.95
1Y Return
152.67%
Buy Reco %
PE Ratio
86.06
1Y Return
34.59%
Buy Reco %
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -4.83%, vs industry avg of 19.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 10.4% to 3.37%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue723.08598.59600.78795.34574.08634.862,348.41614.27621.00586.00
Raw Materialssubtract193.63158.42197.98135.06190.01199.02311.17218.29212.27563.21
Power & Fuel Costsubtract25.1530.5533.5234.5529.7430.9437.8231.9535.95
Employee Costsubtract142.02148.12151.59147.08142.32156.17182.97126.48149.57
Selling & Administrative Expensessubtract104.3586.0768.9294.7783.6975.20102.8770.5670.78
Operating & Other expensessubtract76.2173.7457.06179.6788.7788.3039.60110.63110.66
Depreciation/Amortizationsubtract73.3267.9557.2854.0043.2245.5943.7839.1236.7135.33
Interest & Other Itemssubtract127.33100.93100.58104.83173.98185.34180.844.443.583.52
Taxes & Other Itemssubtract-0.64-12.707.847.6516.611.99371.0446.042.65-0.70
EPS-2.74-8.16-11.085.65-29.10-23.07176.05-5.43-0.19-2.51
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Aug 2PDF
Jul 28PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Panacea Biotec Ltd-2,246.123.11
Biocon Ltd46.511.880.13%
Onesource Specialty Pharma Ltd-45.3144.47
Sai Life Sciences Ltd186.0915.80

Price Comparison

Compare PANACEABIO with any stock or ETF
Compare PANACEABIO with any stock or ETF
PANACEABIO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.49%0.00%1.17%0.38%25.97%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '240.26%0.26%0.27%0.27%0.37%0.38%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

PANACEABIO has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2011

Final
Final | Div/Share: ₹0.75

Dividend/Share

0.75

Ex DateEx Date

Sep 19, 2011

Cash Dividend

Ex DateEx DateSep 16, 2010

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 16, 2010

News & Opinions
Corporate
Panacea Biotec to announce Quarterly Result

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live

6 days agoCapital Market - Live
Corporate
Panacea Biotec Pharma launches 'NikoMom' brand of baby diapers and wipes

Panacea Biotec announced that the company's wholly owned subsidiary, Panacea Biotec Pharma (PBPL) has launched baby diapers and wipes under the brand name 'NikoMom'. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Panacea Biotec announces investment in Panacea Biotec Inc.

Panacea Biotec announced that the company's material subsidiary, Panacea Biotec Pharma (PBCL) has made further investment of US$ 9,25,000 (~Rs.7.92 crore) in its wholly owned subsidiary, Panacea Biotec Inc. (PB Inc.) subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share. Panacea Biotec Inc. being a step-down subsidiary of the company. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Panacea Biotec hits the roof on bagging order worth Rs 127-cr from UNICEF

The contract is worth $14.95 million (approximately Rs 127 crore). The said order will be executed by calendar year 2025, subject to signing of requisite amendment to the long term arrangement. The project entails supply of bOPV to UNICEF for its requirements in countries in Africa and Asia region as per the orders as may be received from time to time. Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported consolidated net loss of Rs 8.29 crore in Q2 FY24 as compared with net profit of Rs 15.70 crore reported in Q2 FY23. Net sales jumped 36.1% YoY to Rs 143.02 crore in Q2 FY24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Panacea Biotec wins order of Rs 127 cr from UNICEF

Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net profit of Rs 4.71 crore in the September 2024 quarter

Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Panacea Biotec to hold board meeting

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Panacea Biotec to hold AGM

Panacea Biotec announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net loss of Rs 15.88 crore in the June 2024 quarter

Net loss of Panacea Biotec reported to Rs 15.88 crore in the quarter ended June 2024 as against net profit of Rs 10.98 crore during the previous quarter ended June 2023. Sales declined 10.43% to Rs 115.72 crore in the quarter ended June 2024 as against Rs 129.19 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales115.72129.19 -10 OPM %-12.09-7.98 - PBDT-11.06-5.23 -111 PBT-19.79-14.71 -35 NP-15.8810.98 PL Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Panacea Biotec reports standalone net loss of Rs 13.78 crore in the June 2024 quarter

Net loss of Panacea Biotec reported to Rs 13.78 crore in the quarter ended June 2024 as against net profit of Rs 1.29 crore during the previous quarter ended June 2023. Sales declined 36.38% to Rs 56.88 crore in the quarter ended June 2024 as against Rs 89.41 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales56.8889.41 -36 OPM %-18.447.62 - PBDT-9.906.69 PL PBT-14.981.29 PL NP-13.781.29 PL Powered by Capital Market - Live

5 months agoCapital Market - Live